IP Library › Granted Patent US 12,213,982
Granted Patent B2
US 12,213,982 · App. 18/235,486 · Granted Feb 4, 2025

Pharmaceutical compositions comprising sepiapterin and uses thereof

Inventor: Daniel E. Levy (San Mateo, CA)
Assignee: PTC Therapeutics MP, Inc.
A61K31/519A61K9/14A61K9/20A61K38/40A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,213,982
App. No.
18/235,486
Granted
Feb 4, 2025
Kind
B2
Abstract

The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and/or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.

Claims (22)

1. A method of treating a tetrahydrobiopterin-related disorder selected from tetrahydrobiopterin deficiency and phenylketonuria in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of sepiapterin and a pharmaceutically acceptable carrier,

wherein the relative amount of antioxidant to sepiapterin is between 0 and 20% wt/wt;

wherein the antioxidant, when present, is ascorbic acid, an ester of ascorbic acid, or a salt of ascorbic acid; and

wherein from about 2.5 mg sepiapterin per kilogram of body weight of the subject (mg/kg) to about 150 mg/kg is administered.

2. The method of claim 1 , wherein from about 40 mg/kg to about 150 mg/kg is administered.

3. The method of claim 1 , wherein from about 60 mg/kg to about 120 mg/kg is administered.

4. The method of claim 1 , wherein from about 40 mg/kg to about 60 mg/kg is administered.

5. The method of claim 1 , wherein from about 2.5 mg/kg to about 20 mg/kg is administered.

6. The method of claim 1 , wherein the tetrahydrobiopterin-related disorder is phenylketonuria.

7. The method of claim 1 , wherein the tetrahydrobiopterin-related disorder is a tetrahydrobiopterin deficiency.

8. The method of claim 7 , wherein the tetrahydrobiopterin deficiency is primary tetrahydrobiopterin deficiency.

9. The method of claim 1 , wherein the pharmaceutical composition comprises less than 1.3% of lactoylpterin by weight of the combined amount of sepiapterin and lactoylpterin in the composition.

10. The method of claim 1 , wherein the pharmaceutical composition is stable at room temperature for at least 6 months.

11. The method of claim 1 , wherein the pharmaceutical composition is formulated as a powder.

12. The method of claim 1 , wherein the composition further comprises a dispersant selected from crosslinked polyvinylpyrrolidone, carboxymethylcellulose, croscarmellose sodium, starch, or alginic acid, wherein the pharmaceutical composition comprises 0.5-1.5% dispersant by total weight.

13. The method of claim 12 , wherein the dispersant is croscarmellose sodium, wherein the composition comprises 1% croscarmellose sodium by weight.

14. The method of claim 1 , wherein the composition further comprises an anti-caking agent or bulking agent selected from colloidal silicon dioxide, microcrystalline cellulose, tricalcium phosphate, microcrystalline cellulose, magnesium stearate, sodium bicarbonate, sodium ferrocyanide, potassium ferrocyanide, calcium ferrocyanide, calcium phosphate, sodium silicate, colloidal silicon dioxide, calcium silicate, magnesium trisilicate, talcum powder, sodium aluminosilicate, potassium aluminum silicate, calcium aluminosilicate, bentonite, aluminum silicate, stearic acid, and polydimethylsiloxane, wherein the composition comprises about 60-80% anti-caking or bulking agent by total weight.

15. The method of claim 14 , wherein the anti-caking or bulking agents are microcrystalline cellulose and silicon dioxide, wherein the composition comprises about 63% microcrystalline cellulose by weight and about 6% colloidal silicon dioxide by weight.

16. The method of claim 1 , wherein the antioxidant is selected from ascorbic acid, ascorbyl palmitate, ascorbyl myristate, ascorbyl stearate, or sodium ascorbate.

17. The method of claim 16 , wherein the antioxidant is ascorbic acid.

18. The method of claim 1 , wherein the composition is substantially free of antioxidant.

19. The method of claim 1 , wherein the pharmaceutical composition comprises about 25% sepiapterin by total weight.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2024
From: LEVY, DANIEL E.
To: CENSA PHARMACEUTICALS INC.
Reel/Frame 069476/0161 →
CHANGE OF NAME Recorded Dec 3, 2024
From: CENSA PHARMACEUTICALS INC.
To: PTC THERAPEUTICS MP, INC.
Reel/Frame 069476/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2023
From: LEVY, DANIEL E.
To: CENSA PHARMACEUTICALS INC.
Reel/Frame 064963/0202 →
CHANGE OF NAME Recorded Sep 20, 2023
From: CENSA PHARMACEUTICALS INC.
To: PTC THERAPEUTICS, INC.
Reel/Frame 064963/0266 →
Continuity (5)
Continuation 16670362 · Oct 31, 2019
Continuation PCTUS2018049359 · Sep 4, 2018
Provisional Application 62678069 · May 30, 2018
Provisional Application 62553603 · Sep 1, 2017
Related Publication 20240100054A1 · Mar 28, 2024
References Cited (138)
US 4758571A · Curtius et al. · 1988 [cited by applicant]
US 4774244A · Curtius et al. · 1988 [cited by applicant]
US 5736343A · Landry · 1998 [cited by applicant]
US 5753656A · Sakai et al. · 1998 [cited by applicant]
US 7566462B2 · Jungles et al. · 2009 [cited by applicant]
US 7566714B2 · Oppenheimer et al. · 2009 [cited by applicant]
US 7582799B2 · Yoshino et al. · 2009 [cited by applicant]
US 7612073B2 · Oppenheimer et al. · 2009 [cited by applicant]
US 7727987B2 · Moser et al. · 2010 [cited by applicant]
US 7732599B2 · Moser et al. · 2010 [cited by applicant]
US 7947681B2 · Oppenheimer et al. · 2011 [cited by applicant]
US 8003126B2 · Jungles et al. · 2011 [cited by applicant]
US 8067416B2 · Oppenheimer et al. · 2011 [cited by applicant]
US 8188043B2 · Cooke et al. · 2012 [cited by applicant]
US 8222422B2 · Hashimoto et al. · 2012 [cited by applicant]
US RE43797E · Oppenheimer et al. · 2012 [cited by applicant]
US 8318745B2 · Moser et al. · 2012 [cited by applicant]
US 8410264B2 · Dai et al. · 2013 [cited by applicant]
US 9181254B2 · Yoshino et al. · 2015 [cited by applicant]
US 9212183B2 · Sieger et al. · 2015 [cited by applicant]
US 9433624B2 · Oppenheimer et al. · 2016 [cited by applicant]
US 9492451B2 · Rustomjee et al. · 2016 [cited by applicant]
US 9993481B2 · Oppenheimer et al. · 2018 [cited by applicant]
US 11072614B2 · Levy · 2021 [cited by applicant]
US 11130760B2 · Yoshino et al. · 2021 [cited by applicant]
US 11173158B2 · Hasegawa et al. · 2021 [cited by applicant]
US 11617752B2 · Smith et al. · 2023 [cited by applicant]
US 11752154B2 · Levy · 2023 [cited by applicant]
US 11773097B2 · Levy · 2023 [cited by applicant]
US 20060040946A1 · Oppenheimer et al. · 2006 [cited by applicant]
US 20070049599A1 · Hesslinger et al. · 2007 [cited by applicant]
US 20070270581A1 · Jungles et al. · 2007 [cited by applicant]
US 20080075666A1 · Dudley et al. · 2008 [cited by applicant]
US 20100130500A1 · Kakkis · 2010 [cited by applicant]
US 20110144117A1 · Widmann et al. · 2011 [cited by applicant]
US 20130108694A1 · Chou et al. · 2013 [cited by applicant]
US 20130197000A1 · Hasegawa et al. · 2013 [cited by applicant]
US 20130237543A1 · Oppenheimer et al. · 2013 [cited by applicant]
US 20130336975A1 · Dutzar et al. · 2013 [cited by applicant]
US 20180078557A1 · Hasegawa et al. · 2018 [cited by applicant]
US 20190308975A1 · Levy · 2019 [cited by applicant]
US 20200009145A1 · Hasegawa et al. · 2020 [cited by applicant]
US 20200010469A1 · Yoshino et al. · 2020 [cited by applicant]
US 20210161901A1 · Smith et al. · 2021 [cited by applicant]
US 20210220363A1 · Smith et al. · 2021 [cited by applicant]
US 20210269443A1 · Levy et al. · 2021 [cited by applicant]
US 20210300930A1 · Levy · 2021 [cited by applicant]
US 20220081443A1 · Yoshino et al. · 2022 [cited by applicant]
CN 1905863A · 2007 [cited by applicant]
CN 101132776A · 2008 [cited by applicant]
CN 101678025A · 2010 [cited by applicant]
CN 104736539A · 2015 [cited by applicant]
JP S5925323A · 1984 [cited by applicant]
JP 2007511536A · 2007 [cited by applicant]
JP 2008520574A · 2008 [cited by applicant]
JP 2010523708A · 2010 [cited by applicant]
JP 2011530540A · 2011 [cited by applicant]
JP 2012207029A · 2012 [cited by applicant]
JP 2013502396A · 2013 [cited by applicant]
JP 201415477A · 2014 [cited by applicant]
JP 2019535836A · 2019 [cited by applicant]
WO WO2005028462A1 · 2005 [cited by applicant]
WO WO2005049000A2 · 2005 [cited by applicant]
WO WO2008128049A2 · 2008 [cited by applicant]
WO WO2010072776A1 · 2010 [cited by applicant]
WO WO2011132435A1 · 2011 [cited by applicant]
WO WO2013168693A1 · 2013 [cited by applicant]
WO WO2017218421A1 · 2017 [cited by applicant]
WO WO2018019931A1 · 2018 [cited by applicant]
WO WO2018102314A1 · 2018 [cited by applicant]
WO WO2018102315A1 · 2018 [cited by applicant]
WO WO2018195321A1 · 2018 [cited by applicant]
WO WO2019046849A1 · 2019 [cited by applicant]
WO WO2021026247A1 · 2021 [cited by applicant]
WO WO2021062264A1 · 2021 [cited by applicant]
“Tetrahydrobiopterin Deficiency,” NORD, <https://web.archive.org/web/20160901103424/https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/>, last updated Sep. 1, 2016, retrieved Feb. 11, 2021 (10 pages). [cited by applicant]
Abell et al., “Effect of oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: a randomized, placebo-controlled, phase 2 trial,” J Diabetes Complications. 35(9):107961 (2021)… [cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates ‘the 100 mg- approach’,” Int J Pharm. 275(1-2):1-12 (2004). [cited by applicant]
Bastin et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities,” Org Proc Res Dev. 4(5):427-35 (Jul. 2000) (10 pages). [cited by applicant]
Bernegger et al., “High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002,” Mol Genet Metab. 77(4):304-13 (2002). [cited by applicant]
Blau et al., “Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of DOPA-responsive dystonia and sepiapterin reductase deficiency,” Mol Genet Metab. 74(1-2):172-85 (2001). [cited by applicant]
Bratkovic et al., “PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study,”… [cited by applicant]
Brittain et al., “Polymorphism in Pharmaceutical Solids,” CRC Press. 192:3-480 (2016). [cited by applicant]
Caira, “Crystalline polymorphism of organic compounds,” [cited by applicant]
ClinicalTrials.gov Identifier: NCT03519711, “A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants with Hyperphenylalaninemia,” <https://clinicaltrials.gov/ct2/show/study/NCT03519711>, first po… [cited by applicant]
Curtius et al., “Atypical phenylketonuria due to tetrahydrobiopterin deficiency. Diagnosis and treatment with tetrahydrobiopterin, dihydrobiopterin and sepiapterin.” Clin Chim Acta. 93(2):251-62 (1979). [cited by applicant]
Duggirala et al., “Pharmaceutical cocrystals: along the path to improved medicines.” Chem Commun. 52(4):640-655 (Jan. 2016) (17 Pages). [cited by applicant]
Grant et al., “Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-… [cited by applicant]
Guillory, Chapter 5: Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids, [cited by applicant]
Haynes et al., “Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database,” J Pharm Sci. 94(10):2111-20 (Oct. 2005). [cited by applicant]
Hennermann et al., “Partial and total tetrahydrobiopterin-responsiveness in classical and mild phenylketonuria (PKU),” J Inherit Metab Dis. 25(Suppl 1):21:041-P (2002) (Abstract only). [cited by applicant]
Hirayama, “Handbook for preparing crystals of organic compounds—Principles and know-how,” pp. 57-85 (Jan. 2008) (21 pages). [cited by applicant]
Ichiyama et al., “Enzymic studies on the biosynthesis of serotonin in mammalian brain,” J Biol Chem. 245(7):1699-709 (1970). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/49359, mailed Nov. 15, 2018 (11 pages). [cited by applicant]
Kaufman, “Phenylalanine hydroxylation cofactor in phenylketonuria,” Science. 128(3337):1506-8 (1958). [cited by applicant]
Klaiman et al., “Tetrahydrobiopterin as a treatment for autism spectrum disorders: a double-blind, placebo-controlled trial,” J Child Adolesc Psychopharmacol. 23(5):320-8 (2013) (11 pages). [cited by applicant]
Kuplennik et al., “Enhanced nanoencapsulation of sepiapterin within PEG-PCL nanoparticles by complexation with triacetyl-beta cyclodextrin,” Molecules. 24(15):2715 (Jul. 2019) (19 pages). [cited by applicant]
Kure et al., “Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency,” J Pediatr. 135(3):375-8 (1999). [cited by applicant]
Kwon et al., “Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages,” J Biol Chem. 264(34):20496-501 (1989). [cited by applicant]
Matalon et al., “Tetrahydrobiopterin (BH4) responsive phenylalanine hydroxylase (PAH) mutations,” J Inherit Metab Dis. 25(Suppl 1):23:045-P (2002) (Abstract only). [cited by applicant]
Mayer et al., “Brain nitric oxide snythase is a biopterin- and flavin-containing multi-functional oxido-reductase,” FEBS Lett. 288(1-2):187-91 (1991). [cited by applicant]
Muntau et al., “Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria,” N Engl J Med. 347(26):2122-32 (2002). [cited by applicant]
Nagatsu et al., “Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis,” J Biol Chem. 239(9):2910-7 (1964). [cited by applicant]
Niederwieser et al., “Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man,” Eur J Pediatr. 138(2):110-2 (1982). [cited by applicant]
Office Action for Japanese Patent Application No. 2019-548533, mailed Oct. 26, 2021 (10 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2019-548534, mailed Nov. 2, 2021 (10 pages). [cited by applicant]
Ono, “Analysis of salt selection of current active pharmaceutical ingredients (API),” Yakuzaigaku. 73(3):176-182 (2013) (8 pages). [cited by applicant]
Opladen et al., “Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies.” Orphanet J Rare Dis. 15(1):126 (May 2020) (30 pages). [cited by applicant]
Park et al., “Optimization of expression conditions enhances production of sepiapterin, a precursor for tetrahydrobiopterin biosynthesis, in recombinant [cited by applicant]
Pfleiderer, “Pteridine, LXVIII. Überführung von biopterin in sepiapterin und absolute konfiguration des sepiapterins,” Chem Ber. 112:2750-2755 (1979). [cited by applicant]
Ponzone et al., “Hyperphenylalaninemia and pterin metabolism in serum and erythrocytes,” Clin Chim Acta. 216(1-2):63-71 (1993). [cited by applicant]
Saeed et al., “Uncertainty of thermal characterization of phase change material by differential scanning calorimetry analysis,” Int J Eng Res Technol. 5(1):405-12 (Jan. 2016). [cited by applicant]
Sawabe et al., “Cellular uptake of sepiapterin and push-pull accumulation of tetrahydrobiopterin,” Mol Genet Metab. 94(4):410-6 (2008). [cited by applicant]
Sawabe et al., Sepiapterin administration raises tissue BH4 levels more efficiently than BH4 supplement in normal mice, [cited by applicant]
Schircks et al., “Herstellung von (6 R, S)-5,6,7,8-Tetrahydro-L-biopterin, 7,8-Dihydro-L-biopterin, L-Sepiapterin, Deoxysepiapterin, (6 R, S)-5,6-Dihydrodeoxysepiapterin und 2′-Deoxybiopterin,” Helvetica Chimica Acta. 6… [cited by applicant]
Schircks et al., “Über Pterinchemie. 65 Mitteilung [1]. Herstellung von (6 R,S)-5,6,7,8-Tetrahydro-L-biopterin, 7,8-Dihydro-L-biopterin, L-Sepiapterin, Deoxysepiapterin, (6 R,S)-5,6-Dihydrodeoxysepiapterin and 2′-Deoxyb… [cited by applicant]
Schircks Laboratories, “Data Sheet: L-Sepiapterin. Product No. 11.225,” published Jan. 26, 2016 (1 page). [cited by applicant]
Schircks Laboratories, “Data Sheet: Tetrahydrobiopterin Tablets,” published Jul. 1, 2009 (1 page). [cited by applicant]
Shah et al., “Pharmaceutical Dosage Forms: Tablets” edited by Larry L. Augsburger, Stephen W. Hoag, 3rd edition, vol. 2, chapter 2, p. 62-67 (2008) (11 pages). [cited by applicant]
Singhal et al., “Drug polymorphism and dosage form design: a practical perspective,” Adv Drug Deliv Rev. 56(3):335-47 (2004). [cited by applicant]
Smith et al., “Exploratory study of the effect of one week of orally administered CNSA-001 (sepiapterin) on CNS levels of tetrahydrobiopterin, dihydrobiopterin and monoamine neurotransmitter metabolites in healthy volun… [cited by applicant]
Smith et al., “Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers,” Mol Genet Metab. 126(4):406-12 (F… [cited by applicant]
Spaapen et al., “Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the art,” Mol Genet Metab. 78(2):93-9 (2003). [cited by applicant]
Stahl, Preparation of water-soluble compounds through salt formation. [cited by applicant]
Sugiura et al., “The structures of the reoxidation products of 7,8-dihydroneopterin,” Bull Chem Soc Jpn. 46(3):939-42 (1973). [cited by applicant]
Takada, “API form screening and selection in drug discovery stage,” Pharm Stage. 6(10):20-25 (2007) (9 pages). [cited by applicant]
Tietz et al., “A new pteridine-requiring enzyme system for the oxidation of glyceryl ethers,” J Biol Chem. 239(12):4081-90 (1964). [cited by applicant]
Viscontini et al., “Fluoreszierende Stoffe aus [cited by applicant]
Woo et al., “Production of sepiapterin in [cited by applicant]
Yoshinaki, [cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations”, [cited by applicant]
Carlson et al., “An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies”, [cited by applicant]
English Translation of Decision of Refusal in JP Application No. 2022-151886 dated Jan. 16, 2024 (4 pages). [cited by applicant]
Kazuhide Ashizawa et al., “Preformulation Studies on the Drug Discovery Stage,” Pharm Stage. 9(6):72-79 (2009) (10 pages). [cited by applicant]
Ono, “A crystalline form screening of medicines,” Pharmacia. 47(11):1014-18 (2011) (6 pages). [cited by applicant]
The Japanese Pharmacopoeia. 17th ed. The Ministry of Health, Labour and Welfare; Tokyo, Japan, pp. 71-74 (Jan. 7, 2016) (10 pages). [cited by applicant]
Yamano, “Process research of new medicines, polymorphism of crystal,” Pharmacia. 45(4):327-32 (2009) (7 pages). [cited by applicant]
Yoshinaki, “Organic compound crystal production handbook,” 57-85 (Jan. 2008) (17 pages). [cited by applicant]
Cited By (1)
US 12,637,465